SynCardia makes Michael Garippa president
This article was originally published in Clinica
Michael Garippa has become the president of SynCardia Systems, an artificial heart specialist. He will concentrate on aiding the firm’s sales, clinical support, training and marketing. Mr Garippa was previously the president and CEO of fellow cardiovascular company TandemHeart for eight years. SynCardia (Tucson, Arizona) sells the SynCardia temporary total artificial heart. The company says that there have been more than 850 implants of the device, which is approved by the US FDA and Health Canada, and has been CE marked for sale in Europe.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals